Answers are grounded in this paper and cite their sources.
Computational study reveals CPD40 as a promising TEAD2 inhibitor, suggesting new therapeutic pathways in oncogenesis.
Oncogenic transcription is triggered by dysregulation of the Hippo signalling pathway through aberrant nuclear accumulation of YAP and TAZ co-activators acting through the TEA-domain (TEAD) transcription factor family. TEAD2 is a clinically validated and structurally tractable target for covalent small-molecule intervention, with its nucleophilic CYS380 residue in a conserved palmitoylation pocket. In the present study, a focused library of forty-five derivatives of N-(3-(4-Chlorophenoxy)-4-methylphenyl)acrylamide was systematically screened for molecular docking against TEAD2 (PDB: 8PUX), exhibiting binding affinities from -8.51 to -10.40 kcal/mol. Eight compounds achieved threshold affinities of -10 kcal/mol or below (CPD1, CPD2, CPD5, CPD9, CPD13, CPD14, CPD40, CPD43). It is observed that the binding pocket defined by ALA304, ALA235, LEU387, ILE408, VAL329 and PHE428 is stabilised by pi-alkyl hydrophobic contacts, pi-sigma interactions, aromatic pi-pi stacking at PHE428 and directional hydrogen bonds (91.1% prevalence). Integrated ADMET profiling identified CPD40 as the most developable lead compound with the most favourable toxicological profile in the series. Monitoring of 100 ns all-atom molecular dynamics simulation of the TEAD2-CPD40 complex established the exceptional binding stability. The RMSD of the protein backbone reached a plateau at 1.3-2.5 Å over the whole trajectory, without indicating unbinding for CPD40. The MM-GBSA based binding free energy decomposition on 1,002 frames yielded a convergent mean of -75.13 ± 5.09 kcal/mol. The acrylamide carbonyl maintained 94% persistent H-bond occupancy with CYS380 confirming optimal pre-reactive geometry for covalent Michael addition. PCA-based free energy landscape analysis resolved two near-isoenergetic (< 0.3 kcal/mol) conformational basins, both retaining full pharmacophoric contacts. The dynamic cross-correlation matrix (DCCM) analysis revealed a pharmacologically relevant allosteric network between the CYS380-proximal loop (residues 380-395) and the anti-correlated ASP305/SER323 pair (r = -0.548). The multi-parametric computational results collectively validate CPD40 as a potent, drug-like covalent TEAD2 lead for further biochemical and cellular development.
No takes yet. Share an insight, caveat, or question.
R et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: